SRP6383
CD319/SLAMF7/CRACC human
recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE)
别名:
19A, CS1, FOAP-12
登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.32
UNSPSC Code:
12352200
Form:
lyophilized
Assay:
≥95% (SDS-PAGE)
Biological source:
human
Recombinant:
expressed in HEK 293 cells
Mol wt:
calculated mol wt 23.2 kDa, observed mol wt 33-48 kDa (DTT-reduced. Protein migrates due to glycosylation. Ser 23 is the predicted N-terminus.)
biological source
human
recombinant
expressed in HEK 293 cells
tag
6-His tagged (C-terminus)
assay
≥95% (SDS-PAGE)
form
lyophilized
mol wt
calculated mol wt 23.2 kDa, observed mol wt 33-48 kDa (DTT-reduced. Protein migrates due to glycosylation. Ser 23 is the predicted N-terminus.)
packaging
pkg of 10 μg, pkg of 50 μg
impurities
<1 EU/μg endotoxin (LAL test)
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... SLAMF7(57823)
General description
Research area: IMMUNO AND CKS
SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. SLAM F7 (signaling lymphocytic activation molecule F7) receptors are expressed on immune cells such as activated T cells, most B cells, antibody-producing plasma cells and natural killer cells and also on myeloid cells. The SLAMF7 gene is mapped to human chromosome 1q23.3.
SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. SLAM F7 (signaling lymphocytic activation molecule F7) receptors are expressed on immune cells such as activated T cells, most B cells, antibody-producing plasma cells and natural killer cells and also on myeloid cells. The SLAMF7 gene is mapped to human chromosome 1q23.3.
Biochem/physiol Actions
SLAMF7 (signaling lymphocytic activation molecule F7) is considered as a self-ligand which identifies another SLAMF7 expressed on the cell. Apart from immune cells, SLAMF7 is highly expressed in multiple myeloma cells.Isoform 1 of SLAMF7 mediates natural killer (NK) cell activation through a SH2 domain containing 1A (SH2D1A)-independent extracellular signal-regulated extracellular signal-regulated kinases (ERK) mediated pathway. It may play a role in lymphocyte adhesion.Isoform 3 of SLAMF7 does not mediate any NK cell activation.
Physical form
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.
Preparation Note
Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 μg/mL. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Immune cell inhibition by SLAMF7 is mediated by mechanism requiring Src kinases, CD45 and SHIP-1 defective in multiple myeloma cells.
Guo H, et al.
Molecular and Cellular Biology (2014)
Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer.
Kanda M, et al.
International Journal of Cancer. Journal International Du Cancer, 139(10), 2290-2298 (2016)
Controlling natural killer cell responses: integration of signals for activation and inhibition.
Long E O, et al.
Annual Review of Immunology, 31, 227-258 (2013)
SLAM receptors and SAP influence lymphocyte interactions, development and function.
Schwartzberg P L, et al.
Nature Reviews: Immunology, 9(1), 39-39 (2009)
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
Kuroda J, et al.
Expert Review of Anticancer Therapy, 13(9), 1081-1088 (2013)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持